Exposure variability and target attainment of vancomycin: a systematic review comparing intermittent and continuous infusion

EM van Maarseveen, SGH Gipmans… - Therapeutic drug …, 2020 - journals.lww.com
… vancomycin intermittent infusion (InI) and continuous infusion (CoI… and target attainment with
vancomycin during InI and CoI. … exposure variability and target attainment with InI and CoI in …

Population pharmacokinetics of piperacillin following continuous infusion in critically ill patients and impact of renal function on target attainment

V Klastrup, A Thorsted, M Storgaard… - Antimicrobial agents …, 2020 - Am Soc Microbiol
… of target attainmenttarget attainment for the 100% fT > 4× MIC target. To conclude, in
patients with high CRCL combined with high-MIC bacterial infections, even a continuous infusion (…

Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a …

DC Richter, O Frey, A Röhr, JA Roberts, A Köberer… - Infection, 2019 - Springer
… We primarily assessed PIP target attainment within the first 24 h of treatment and further
investigated the effect of subsequent TDM-guided dose adjustments on PK-target attainment to …

Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: a prospective observational study

SAM Dhaese, ADJ Thooft, A Farkas, J Lipman… - Journal of Critical …, 2019 - Elsevier
… In this study, the aim was to describe clinical target attainment of empirically dosed,
continuously infused TZP and MER in ICU patients. Empirical dosing regimens are designed to …

Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa

B Pilmis, G Petitjean, P Lesprit, M Lafaurie… - European Journal of …, 2019 - Springer
infusion can better achieve the pharmacodynamic target than … the use of prolonged or
continuous infusion with intermittent … to evaluate continuous, prolonged, or intermittent infusion of …

Target attainment through algorithm design during intravenous insulin infusion

R Devi, T Zohra, BS Howard… - Diabetes Technology & …, 2014 - liebertpub.com
… A treatment course was adjudicated if it was ordered generically as a continuous infusion
of regular insulin, without chart order for use of a specific algorithm, or if the conservative or …

Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients

J Martínez-Casanova, E Esteve-Pitarch… - Antibiotics, 2023 - mdpi.com
… by continuous infusion (CI) improves pharmacokinetic/pharmacodynamic (PK/PD) target
attainment. … For the PK/PD target of 100% fT >1×MIC , 12 g of piperacillin provide a probability of …

… joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted …

M Gatti, M Rinaldi, C Bonazzetti, P Gaibani… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
… even more aggressive and stable PK/PD target attainment at the infection site with better …
infusion (5, 17). This may support the contention that optimizing joint PK/PD target attainment of …

[HTML][HTML] … pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion

S Tournayre, O Mathieu, M Villiet, N Besnard… - International Journal of …, 2023 - Elsevier
Objectives The use of extended intermittent infusion (EII) or continuous infusion (CI) of
meropenem is recommended in intensive care unit (ICU) patients, but few data comparing these …

Could an optimized joint Pharmacokinetic/Pharmacodynamic target attainment of continuous infusion Piperacillin-Tazobactam be a Valuable innovative Approach for …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - Antibiotics, 2023 - mdpi.com
… We aimed to assess the relationship between the joint PK/PD target attainment of
continuous infusion (CI) piperacillin-tazobactam and the microbiological/clinical outcome of …